Hanall Biopharma Co., Ltd.

Total Valuation

Hanall Biopharma Co., Ltd. carries a market capitalization of 2.84T, placing it among publicly traded companies globally. Its enterprise value stands at 2.90T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Hanall Biopharma Co., Ltd. currently has 50.78M shares outstanding.

Valuation Ratios

Hanall Biopharma Co., Ltd. trades at a trailing price-to-earnings ratio of 976.65. The price-to-sales ratio is 18.21, and the price-to-book ratio stands at 60.94.

Enterprise Valuation

On an enterprise value basis, Hanall Biopharma Co., Ltd. trades at an EV/EBITDA multiple of 9,150.20 and an EV/FCF ratio of 216.88. The EV/Sales ratio of 18.26 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9,150.20 provides insight into valuation relative to core operating earnings.

Financial Position

Hanall Biopharma Co., Ltd. maintains a current ratio of 1.60, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.22, indicating elevated leverage, while an interest coverage ratio of 0.64 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Hanall Biopharma Co., Ltd. has paid -125.56M in income taxes, reflecting an effective tax rate of 107.32.

Stock Price Statistics

Hanall Biopharma Co., Ltd.'s stock has gained approximately 118.78669% over the past 52 weeks. The 50-day moving average sits at 52,638.00, while the 200-day moving average is 48,167.00.

Income Statement

Over the trailing twelve months, Hanall Biopharma Co., Ltd. generated 159.06B in revenue and converted that into -5.08B in net income, yielding earnings per share of -96.94. EBITDA reached 317.37M, while operating income came in at 317.37M.

Balance Sheet

Hanall Biopharma Co., Ltd. holds 36.16B in cash and equivalents against 44.20B in total debt, resulting in a net debt position of 7.01B. Total book value stands at 47.52B, with working capital of 38.25B providing operational flexibility.

Cash Flow

Hanall Biopharma Co., Ltd. produced -732.36M in operating cash flow over the past twelve months. After subtracting -13.64B in capital expenditures, free cash flow totaled -14.37B - equivalent to -274.45 per share.

Margins

Hanall Biopharma Co., Ltd. operates with a gross margin of 52.16, reflecting its pricing power and cost economics. The operating margin of 0.20 and net profit margin of -3.19 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Hanall Biopharma Co., Ltd.'s most recent stock split took place on May 3, 2006 with a 1:10 split ratio.

Scores

Hanall Biopharma Co., Ltd. posts an Altman Z-Score of 22.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.